Richard K. Cheng

发表

A false measure of success "I'd rather have an ounce of cure over this 200 pounds of prevention" [Web development]

Richard K. Cheng, 2005, Agile Development Conference (ADC'05).

Cyclin A2 Induces Cardiac Regeneration After Myocardial Infarction and Prevents Heart Failure

Richard K. Cheng, E. Wu, K. Costa, 2007, Circulation research.

Therapeutic Delivery of Cyclin A2 Induces Myocardial Regeneration and Enhances Cardiac Function in Ischemic Heart Failure

Richard K. Cheng, P. Atluri, J. Cohen, 2006, Circulation.

Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association

Richard K. Cheng, Jagmeet P. Singh, Theresa M. Beckie, 2021, Circulation.

Cyclin A2 Induces Cardiac Regeneration After Myocardial Infarction Through Cytokinesis of Adult Cardiomyocytes

Mario J. Garcia, Richard K. Cheng, Y. Kawase, 2014, Science Translational Medicine.

Association of soluble Flt-1 with heart failure and cardiac morphology: The MESA angiogenesis study.

Richard K. Cheng, D. Bluemke, J. Lima, 2022, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Training and Career Development in Cardio-Oncology Translational and Implementation Science.

Richard K. Cheng, Sherry‐Ann Brown, Craig J. Beavers, 2022, Heart failure clinics.

Novel Therapeutics for Anthracycline Induced Cardiotoxicity

Richard K. Cheng, E. Yang, A. Stein-Merlob, 2022, Frontiers in Cardiovascular Medicine.

Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case–Control Study and Literature Review

Richard K. Cheng, J. Liao, D. Hippe, 2022, Cancers.

Ten step academic-industry digital health collaboration methodology: A case-based guide for digital health research teams with the example of cardio-oncology

Richard K. Cheng, Sherry‐Ann Brown, D. Addison, 2022, Frontiers in Cardiovascular Medicine.

Advanced Heart Failure Therapies: Specific Considerations for Cardio-Oncology Patients

Richard K. Cheng, D. Dimitri, Mahyar Pourriahi, 2022, Current Treatment Options in Cardiovascular Medicine.

Inhibitors of metabolism rescue cell death in Huntington's disease models

Richard K. Cheng, B. Stockwell, A. Hart, 2007, Proceedings of the National Academy of Sciences.

Commentary: “Multimodality advanced cardiovascular and molecular imaging for early detection and monitoring of cancer therapy-associated cardiotoxicity and the role of artificial intelligence and big data”

Richard K. Cheng, Sherry‐Ann Brown, Louise Y. Sun, 2023, Frontiers in Cardiovascular Medicine.

An Opportunity to Refine Our Understanding of Right Ventricular Involvement in Cardiac Sarcoidosis.

Richard K. Cheng, B. Nazer, 2023, JACC. Cardiovascular imaging.

Cardiometabolic Consequences of Targeted Anticancer Therapies

Richard K. Cheng, N. Agarwal, S. Dent, 2021, Journal of cardiovascular pharmacology.

Trends in Cardiovascular Medicine Editorial commentary: Searching for the sweet spot of cardioprotection in cancer treatment related cardiotoxicity: Who will beneﬁt?

Richard K. Cheng, E. Yang, 2019 .

Burden and prognostic impact of cardiovascular disease in patients with cancer

Richard K. Cheng, C. Manisty, M. Mamas, 2023, Heart.

Regional variations in heart failure: a global perspective

Richard K. Cheng, M. Mamas, H. V. Van Spall, 2023, Heart.

Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2.

Richard K. Cheng, P. Atluri, H. Chaudhry, 2007, The Journal of thoracic and cardiovascular surgery.

Assessment of Left Ventricular, Right Ventricular, and Left Atrial Strain in Light-Chain Amyloidosis

Richard K. Cheng, J. Kirkpatrick, A. Cowan, 2020, JACC. CardioOncology.

Implications of and potential solutions for the weekend effect in heart transplantation.

Richard K. Cheng, Shin-Jie Lin, 2022, The Journal of Heart and Lung Transplantation.